PET imaging with 68Ga-XT771 to detect CAIX/CAXII in glioblastoma and clear cell renal cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, open-label early phase 1 imaging study of 68Ga-XT771, a PET probe that targets the CAIX/CAXII proteins, in adults with glioblastoma or clear cell renal cell carcinoma. Participants will receive 68Ga-XT771 and undergo PET/CT imaging to characterize tracer uptake, biodistribution, safety, and tolerability. The study will collect imaging and safety data to determine how well the tracer detects CAIX/CAXII-expressing tumors and to describe its pharmacokinetics. Conducted at the Chinese PLA General Hospital, the trial is intended as an initial clinical evaluation to inform future larger studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. signed the informed consent 2. ≥18 years old 3. Patients with glioblastoma or clear cell renal cell carcinoma

Exclusion Criteria:

* 1\. Known allergy to components of the investigational drug or its analogues 2. suspected to have a certain disease or condition that is not suitable for the study drug 3. Known pregnant or lactating women

Where it's running

• Chinese PLA General Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Ruimin Wang
• Email: wrm@yeah.net
• Phone: +8613501151740

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• Immune cell therapy for advanced clear cell kidney cancer

  This study tests a patient's own tumor-infiltrating lymphocytes (TIL) therapy, given after conditioning with chemotherapy and then interleukin-2, in adults with advanced clear cell renal cell carcinoma who have tried prior treatments.

  Recruiting at 2 sites Phase 1 Hangzhou Huasai Biomedicine Co., Ltd. · Beijing and 1 other locations · NCT07770802

• Theranostic pair labeled PD-32766D/T in CA9-positive clear cell kidney cancer

  This study tests a matching diagnostic agent PD-32766D and a therapeutic agent PD-32766T in adults with CA9-expressing clear cell renal cell carcinoma to see if the treatment is safe and shows signs of effect.

  Recruiting Phase 1 PeptiDream Inc. · Omaha, Nebraska · NCT07688187

• LNK001 CAR T therapy in advanced clear cell kidney cancer

  This study tests a CAR T-cell therapy called LNK001 to see if it can help people with advanced clear cell renal cell carcinoma after other treatments.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07564232

• Neoadjuvant immunotherapy with botensilimab and balstilimab for high-risk non-metastatic clear cell RCC

  This trial tests whether giving botensilimab and balstilimab before kidney tumor surgery is safe and helps patients with high‑risk non‑metastatic clear cell RCC proceed to nephrectomy.

  Recruiting at 5 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 4 other locations · NCT07516366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.